This 10-year follow-up analysis of the ShortHER randomized clinical trial evaluates the association of tumor-infiltrating lymphocytes with distant disease-free and overall survival among patients with ERBB2 (formerly HER2)–positive early breast cancer. Here, ERBB2 is linked to neoplasm.